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Abstract
Background: Twenty four non replicate imipenem resistant P. aeruginosa were isolated between January and
November 2008, in the kidney transplantation unit of Charles Nicolle Hospital of Tunis (Tunisia). This study was
conducted in order to establish epidemiological relationship among them and to identify the enzymatic
mechanism involved in imipenem resistance.
Methods: Analysis included antimicrobial susceptibility profile, phenotypic (imipenem-EDTA synergy test) and
genotypic detection of metallo-b-lactamase (MBL) (PCR), O-serotyping and pulsed-field gel electrophoresis.
Results: All strains showed a high level of resistance to all antimicrobials tested except to colistin. The presence of
MBL showed concordance between phenotypic and genotypic methods. Sixteen isolates were identified as VIM-2
MBL-producers and 13 of them were serotype O4 and belonged to a single pulsotype (A).
Conclusions: This study describes an outbreak of VIM-2-producing P. aeruginosa in a kidney transplantation unit.
Clinical spread of blaVIM-2 gene is a matter of great concern for carbapenem resistance in Tunisia.
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Background
Pseudomonas aeruginosa is a frequent nosocomial
pathogen that causes a wide range of opportunistic
infections and nosocomial outbreaks [1-3]. Its high
intrinsic resistance to antibiotics and ability to develop
multidrug resistance pose serious therapeutic problems.
Four broad-spectrum b-lactams, such as carbapenems,
are potential drugs for the therapy of infections caused
by P. aeruginosa [4,5]. However, the increasing use of
these compounds has resulted in the emergence of car-
bapenem-resistant P. aeruginosa isolates, limiting treat-
ment options [6,7]. Most carbapenem resistance is due
to impermeability, which arises via loss of the OprD
(D2) porin, but carbapenem hydrolysing metallo-b-lacta-
mases (MBLs) are increasingly reported [8]. Genes
encoding MBLs are located as cassettes in integrons that
provide them with the potential for expression and dis-
semination [9,10]. To date, nine MBL types, namely,
IMP-like[9], VIM-like[9], SPM-1[11], GIM-1[12], SIM-1
[13], AIM-1[14], KHM-1[15], NDM-1[16] and DIM-1
[17], have been identified in Gram negative bacilli.
Worldwide, the IMP and VIM types are the most com-
monly detected MBLs in P. aeruginosa [9,10]. VIM-type
MBLs are predominant in the Mediterranean region
[9,10].
At Charles Nicolle hospital of Tunisia, since Novem-
ber 2002, VIM-2 producing P. aeruginosa has been iso-
lated, mainly in surgery and intensive care unit [18]. In
2008, an increasing rate of imipenem resistance in P.
aeruginosa was observed in the kidney transplantation
unit. The aim of the present study was to determine the
occurrence of MBL genes among imipenem resistant
isolates and to establish epidemiological relationship
among them.
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Patients, Bacterial strains, Serotyping and susceptibility
testing
Twenty four non duplicate imipenem resistant P. aeru-
ginosa isolates were recovered between January and
November 2008 in the kidney transplantation unit of
Charles Nicolle hospital of Tunis. They were isolated
from urine (n = 20), cutaneous pus (n = 3) and blood
(n = 1).
All samples were taken for microbial diagnosis from
24 different patients [sex ratio 3.8]. The median age of
the patients was 51 years [range: 34 to 80 years]. They
were admitted in the urology unit (n = 10) and nephrol-
ogy unit (n = 14).
A retrospective review was conducted for only 15
patients (6 from urology unit, 9 from the nephrology
unit). Date of transplantation was mentioned in Table
1. However, no data concerning kind of transplanta-
tion and live donator was collected. All patients pre-
sented chronic renal failure associated in 13 cases to
at least one underlying co-morbidity [High blood
pressure (n = 13), systemic lupus erythematosis (n =
1), diabetes (n = 1), chronic glomerulonephritis (n =
5), nephritic syndrome (n = 1) and renal tuberculosis
(n = 1)]. In all patients fever was the major symptom.
Ceftazidime combination therapy with colistin
accounted for all patients. Attributable mortality was
5% of cases.
Bacterial identification was performed using ApiNE
(bio-Mérieux, Marcy-l’Etoile, France). O-serotyping was
determined by slide agglutination test using polyvalent
antisera and 16 monovalent antisera numbered O1-O16
according to the manufacturer’s instructions (Bio-Rad,
Marnes-La-Coquette, France).
Antimicrobial susceptibility was tested with the agar
disk diffusion method according to the CLSI guidelines
[19]. The MICs of ticarcillin, ticarcillin + clavulanic acid,
ceftazidime, aztreonam, cefepime, imipenem and mero-
penem were determined using the dilution method in
Mueller Hinton agar according to the CLSI guidelines
[19]. E. coli ATCC 25922 and P. aeruginosa ATCC
27853 were used as control strains.
To detect MBL production, the imipenem-EDTA
synergy test was used [20]. An enlargement of the inhi-
bition zone of imipenem facing the disc of EDTA was
considered as a positive test.
PCR amplification
For the detection of blaVIM and blaIMP genes PCR
experiments were performed using consensus primers as
described previously [21]. Primers specific for blaVIM-2
were also used [22].
Clonal relationship by Pulsed-Field Gel Electrophoresis
(PFGE)
Molecular typing of MBL producing isolates was carried
out, as described previously by Pulsed-Field Gel Electro-
phoresis (PFGE) using SpeI restriction endonuclease
[23]. Clonal relationships based on PFGE patterns were
interpreted according to the criteria proposed by Ten-
over et al [24].
Results and discussion
Carbapenems are potent agents against multiresistant
Gram negative bacilli, including P. aeruginosa,b u t
their efficacy is increasingly compromised by the emer-
gence and the worldwide dissemination of carbapenem
resistance strains, which are implicated in large out-
breaks as described in many countries [1,25]. In Tuni-
sia, frequencies of imipenem resistant P. aeruginosa
varies between 16% and 37.6% [26-28]. At Charles
Nicolle Hospital of Tunis, their frequency was stable
until 2004 (1%), but increased dramatically from 2005
(25%). They were mainly isolated in surgery and inten-
sive care unit [18], but in 2008, an increasing rate of
multidrug-resistant P. aeruginosa was observed in the
kidney transplantation unit. All strains exhibited a
multidrug-resistant phenotype; they were resistant to
antipseudomonal b-lactams (including aztreonam),
aminoglycosides and fluoroquinolones. They remained
susceptible only to colistin which is used for the treat-
ment of our kidney transplanted patients despite its
renal toxicity [29]. MICs results are shown in table 1.
All strains showed a high level of resistance to all b-
lactams, particularly to carbapenems (> 512 μg/ml).
Only 16 strains (67%) were positive according to the
imipenem-EDTA synergy test, suggesting the presence
of MBLs. The acquisition of a MBL gene alone does
not necessarily confer elevated level of resistance to
carbapenems. Indeed, secondary changes in regulatory
system of MBL gene expression, outer membrane per-
meability, active efflux systems in bacterial membrane,
and/or multiplication of structure gene might well be
implicated in acquisition of high-level carbapenem
resistance [30,31]. Aztreonam is the only b-lactam that
may remain fully active against MBL producers [8],
h o w e v e ra l lo u rs t r a i n sw e r er e s i s t a n tt ot h i sb-lactam,
suggesting the occurrence of other mechanisms of b-
lactam resistance [32]. The eight MBL negative strains
were also resistant to all antibiotic tested (Table 1),
but the mechanism involved in the resistance has not
been further examined.
The 16 MBLs-producer strains were positive for bla-
VIM-2 gene and none strain harboured the blaIMP gene
(Table 1). In Tunisia, the most common MBL identified
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wide [9,33,34]. Historically, the first reports of MBLs
genes were VIM-2 and VIM-4 types in P. aeruginosa
[18,35] and K. pneumoniae [36] respectively.
Serotyping identified 3 serotypes: O4 (n = 16), O11 (n
= 4) and O12 (n = 1) (table 1). Only 2 strains were non-
typeable with monovalent antisera. In Tunisia [37] as
well as in many European countries [38], it has been
repeatedly demonstrated over the past 20 years that ser-
otypes O11 and O12 dominate among multiresistant P.
aeruginosa isolates. The 16 MBL-positive strains were
divided into 3 pulsotypes designed A (n = 13), B (n = 2)
and C (n = 1) (Table 1). The 13 strains of pulsotype A
were of serotype O4. These results imply that the disse-
mination of VIM-2 in our kidney transplantation unit
was mainly due to the of spread clonal strains, however,
unrelated VIM-2-harboring strains occurred. Outbreaks
of VIM b-lactamase-producing P. aeruginosa have been
also reported in Greece [3], Italy [2] and Kenya [39], but
there is still very limited knowledge on the epidemiology
of MBLs in Africa.
The emergence of acquired MBLs among P. aerugi-
nosa represents an epidemiological risk for at least two
reasons: firstly, MBLs confer resistance not only to car-
bapenems but to virtually all b-lactams and are fre-
quently associated with resistance to aminoglycosides;
and secondly, genes encoding for MBL enzymes are
most commonly carried on mobile genetic elements
(integrons, plasmids, transposons) that can spread hori-
zontally among unrelated strains [9,18].
Indeed, the blaVIM-2 gene was found in strains of dif-
ferent genotypes (A, B and C), reflecting its ability to
transfer from one bacterium to another.
Conclusion
In conclusion, we found an outbreak of VIM-2-produ-
cing P. aeruginosa in a kidney transplantation unit.
Thus, blaVIM-2 gene may have been spreading in Gram
negative rod in Tunisia. This emphasizes the necessity
of early recognition of MBL producing isolates, rigorous
infection control, and restricted clinical use of broad-
spectrum b-lactams including carbapenems.
Table 1 Characteristics of imipenem resistant P. aeruginosa strains
MICs
Strains Date of
transplantation
Date of
Isolation
Age/
Gender
Speciman EDTA
test
PCR
VIM-
2
Serotype TIC TCC IMP MEM CAZ AZT FEP PFGE
1 27/11/2007 04/01/2008 45/F Cu Pus - - O11 > 2048 > 1024 256 512 2048 > 512 > 256 ND
2 - 23/01/2008 54/M Urine + + O11 > 2048 > 1024 > 512 > 512 64 > 512 > 256 C
3 NT 06/02/2008 61/M Urine - - O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 ND
4 - 10/04/2008 47/M Urine + + O11 > 2048 > 1024 > 512 > 512 64 > 512 > 256 C
5 7/12/2007 12/05/2008 45/F Cu Pus - - NA > 2048 > 1024 > 512 512 1024 > 512 > 256 ND
6 - 20/05/2008 61/M Urine + + O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 A
7 - 20/05/2008 52/M Urine - - O12 > 2048 > 1024 > 512 512 512 > 512 > 256 ND
8 20/12/2007 18/06/2008 45/F Cu Pus - - O11 > 2048 > 1024 > 512 > 512 512 > 512 > 256 ND
9 - 24/06/2008 75/M Urine - - O4 > 2048 > 1024 512 > 512 1024 > 512 > 256 ND
10 NT 04/07/2008 63/M Urine + + O4 > 2048 > 1024 > 512 > 512 1024 > 512 > 256 A
11 08/07/2008 09/07/2008 34/M Urine + + O4 > 2048 > 1024 > 512 > 512 1024 > 512 > 256 A
12 - 21/07/2008 52/M Urine + + O4 > 2048 > 1024 > 512 > 512 1024 > 512 > 256 A
13 - 26/07/2008 54/M Urine - - O4 > 2048 > 1024 > 512 512 1024 > 512 > 256 ND
14 - 02/08/2008 76/M Urine + + NA > 2048 > 1024 > 512 512 64 > 512 256 D
15 16/07/2008 02/08/2008 42/M Urine + + O4 > 2048 > 1024 > 512 > 512 256 > 512 > 256 A
16 10/08/2008 21/08/2008 52/M Urine + + O4 > 2048 > 1024 > 512 512 512 > 512 > 256 A
17 18/08/2008 26/08/2008 52/M Urine + + O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 A
18 - 03/10/2008 20/M Urine + + O4 > 2048 > 1024 > 512 32 64 > 512 > 256 A
19 28/08/2008 06/10/2008 80/M Urine - - NA > 2048 > 1024 > 512 > 512 4 > 512 > 256 ND
20 - 01/11/2008 54/M Urine + + O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 A
21 17/10/2008 05/11/2008 31/M Urine + + O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 A
22 05/11/2008 17/11/2008 34/F Blood + + O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 A
23 15/11/2008 17/11/2008 34/F Urine + + O4 > 2048 > 1024 > 512 > 512 512 > 512 > 256 A
24 10/09/2008 22/11/2008 52/M Urine + + O4 > 2048 > 1024 > 512 > 512 1024 > 512 > 256 A
TIC: Ticarcillin; TCC: Ticarcillin-clavulanic acid; IMP: Imipenem; MEM: Meropenem; CAZ: Ceftazidim; AZT: Aztreonam; FEP: Cefepime; -: clinical data Not found; NT:
No Tranplantation; Cu Pus: Cutaneous Pus; NA: Non Agglutinable; ND: Not determined.
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